GlassScriptPhysician profile
Debra A Narcisse
NPI 1306039623
$4,810.19
in general payments reported to CMS, 2019-2025
31 companies · $2,051 in 2025
The $2,051 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.34 · 2022: $621 · 2023: $527 · 2024: $1,595 · 2025: $2,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,172.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $786.83 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $491.29 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $421.14 | 2022-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $355.60 | 2022-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $342.41 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $200.21 | 2024-2025 | Voquezna |
| Abbvie INC. | $185.28 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $169.06 | 2024-2025 | Rexulti |
| Madrigal Pharmaceuticals | $161.90 | 2025 | Rezdiffra |
| Medtronic, INC. | $150.00 | 2025 | Interstim |
| Neurocrine Biosciences, INC. | $134.32 | 2023-2025 | Ingrezza |
| Exact Sciences Corporation | $133.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $124.68 | 2024-2025 | Veozah |
| Biogen, INC. | $117.65 | 2024 | Zurzuvae |
| Abiomed | $113.79 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $105.77 | 2024 | Valtoco |
| Acadia Pharmaceuticals INC | $93.29 | 2024 | Nuplazid |
| Ultragenyx Pharmaceutical INC. | $85.69 | 2022-2023 | |
| Lundbeck LLC | $84.13 | 2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.00 | 2025 | |
| Sanofi Pasteur INC. | $76.96 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.41 | 2022-2024 | Spiriva Respimat, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.73 | 2023-2025 | Xifaxan, Trulance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.09 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $43.40 | 2022 | |
| Merck Sharp & Dohme LLC | $42.21 | 2022-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Boston Scientific Corporation | $25.71 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.10 | 2022 | |
| Becton, Dickinson and Company | $18.25 | 2023 | Bd Onclarity |
| Jazz Pharmaceuticals INC. | $17.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Narcisse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.